Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lieven Annemans

Showing results (81-90 of 261) with videos related to

Pageof 27
Sort By:
Clinical Drug Investigation|July 5, 2008
Voriconazole treatment of invasive aspergillosis: real-world versus health-economic model resultsHilde Van Campenhout, Sophie Marbaix, Marie-Paule Derde, et al.
BJU International|August 18, 2005
The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysisLieven Annemans, Irina Cleemput, Mark Lamotte, et al.
Clinical Therapeutics|March 15, 2005
A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in BelgiumKoen Demyttenaere, Michiel E H Hemels, Joumana Hudry, et al.
BMC Public Health|January 9, 2026
What moves you? The relation between exercise motivation and well-being using a person-centered approachSara Claes, Sterre De Wit, Bart Le Clercq, et al.
International Journal of Psychiatry in Clinical Practice|June 19, 2014
Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopramChristophe Lançon, Patrice Verpillat, Lieven Annemans, et al.
Frontiers in Public Health|February 3, 2017
Methodological Considerations in Social Cost Studies of Addictive Substances: A Systematic Literature ReviewNick Verhaeghe, Delfine Lievens, Lieven Annemans, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|March 11, 2005
What reimbursement for coronary revascularization with drug-eluting stents?Rosanna Tarricone, Monia Marchetti, Mark Lamotte, et al.
Pharmacoeconomics|February 12, 2004
Education in pharmacoeconomics: an international multidisciplinary viewKaren L Rascati, Michael F Drummond, Lieven Annemans, et al.
Journal of Medical Economics|February 16, 2013
Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in BelgiumPierre Chevalier, Mark Lamotte, Hilde Van Campenhout, et al.
Plos One|November 5, 2016
Effectiveness of Pricing Strategies on French Fries and Fruit Purchases among University Students: Results from an On-Campus Restaurant ExperimentTom Deliens, Benedicte Deforche, Lieven Annemans, et al.
Pageof 27

Showing results (81-90 of 261) with videos related to

Sort By:
Pageof 27
Clinical Drug Investigation|July 5, 2008
Voriconazole treatment of invasive aspergillosis: real-world versus health-economic model resultsHilde Van Campenhout, Sophie Marbaix, Marie-Paule Derde, et al.
BJU International|August 18, 2005
The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysisLieven Annemans, Irina Cleemput, Mark Lamotte, et al.
Clinical Therapeutics|March 15, 2005
A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in BelgiumKoen Demyttenaere, Michiel E H Hemels, Joumana Hudry, et al.
BMC Public Health|January 9, 2026
What moves you? The relation between exercise motivation and well-being using a person-centered approachSara Claes, Sterre De Wit, Bart Le Clercq, et al.
International Journal of Psychiatry in Clinical Practice|June 19, 2014
Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopramChristophe Lançon, Patrice Verpillat, Lieven Annemans, et al.
Frontiers in Public Health|February 3, 2017
Methodological Considerations in Social Cost Studies of Addictive Substances: A Systematic Literature ReviewNick Verhaeghe, Delfine Lievens, Lieven Annemans, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|March 11, 2005
What reimbursement for coronary revascularization with drug-eluting stents?Rosanna Tarricone, Monia Marchetti, Mark Lamotte, et al.
Pharmacoeconomics|February 12, 2004
Education in pharmacoeconomics: an international multidisciplinary viewKaren L Rascati, Michael F Drummond, Lieven Annemans, et al.
Journal of Medical Economics|February 16, 2013
Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in BelgiumPierre Chevalier, Mark Lamotte, Hilde Van Campenhout, et al.
Plos One|November 5, 2016
Effectiveness of Pricing Strategies on French Fries and Fruit Purchases among University Students: Results from an On-Campus Restaurant ExperimentTom Deliens, Benedicte Deforche, Lieven Annemans, et al.
Pageof 27